The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 17, Issue 12, Pages 1299-1311
Publisher
Informa UK Limited
Online
2022-12-13
DOI
10.1080/17460441.2022.2153828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
- (2022) Wen Wen et al. ANNALS OF MEDICINE
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
- (2022) Laura Vangeel et al. ANTIVIRAL RESEARCH
- SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
- (2022) Pengfei Li et al. CELL RESEARCH
- Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
- (2022) Mohammad Bosaeed et al. CLINICAL MICROBIOLOGY AND INFECTION
- Nucleosides and emerging viruses: a new story
- (2022) Vincent Roy et al. DRUG DISCOVERY TODAY
- Safety profile of COVID-19 drugs in a real clinical setting
- (2022) Mei Nee Chiu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta subvariant AY.4 of SARS‐CoV‐2
- (2022) Ismail Celik et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
- (2022) David C. Schultz et al. NATURE
- A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
- (2022) Rikin Patel et al. Human Vaccines & Immunotherapeutics
- Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
- (2022) Xuanting Wang et al. Communications Biology
- An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
- (2022) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- (2022) Richard FitzGerald et al. CLINICAL INFECTIOUS DISEASES
- Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach
- (2022) Adem Kara et al. DRUG AND CHEMICAL TOXICOLOGY
- Molnupiravir; molecular and functional descriptors of mitochondrial safety
- (2022) K.B. Wallace et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
- (2022) Manaf AlQahtani et al. Scientific Reports
- SARS-CoV-2 reinfection and COVID-19 severity
- (2022) Nhu Ngoc Nguyen et al. Emerging Microbes & Infections
- Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
- (2022) Shao-Huan Lan et al. Expert Review of Clinical Pharmacology
- Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
- (2022) Maria Costantino et al. Journal of Clinical Medicine
- Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
- (2022) Geehan Suleyman et al. Open Forum Infectious Diseases
- Identification of Drug Interaction Adverse Events in Patients With COVID-19
- (2022) Valeria Conti et al. JAMA Network Open
- Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases
- (2022) Shini Rubina S K et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
- (2022) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
- (2022) Lia Fiaschi et al. Viruses-Basel
- SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
- (2022) Carolin M. Lieber et al. Nature Communications
- SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19
- (2021) Ilaria Vicenti et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19
- (2021) Steven S. Good et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Small-molecule antiviral agents in ongoing clinical trials for COVID-19
- (2021) Çağla Begüm Apaydın et al. CURRENT DRUG TARGETS
- Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
- (2021) Nicola Borbone et al. MOLECULES
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Characteristics of viral pneumonia in the COVID-19 era: an update
- (2021) P. Pagliano et al. INFECTION
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
- (2021) Kyle Rosenke et al. Nature Communications
- An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)
- (2021) Pasquale Pagliano et al. Expert Opinion on Drug Discovery
- A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase
- (2021) Suliman Khan et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- (2021) Florence Ader et al. LANCET INFECTIOUS DISEASES
- Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
- (2021) Florian Kabinger et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay
- (2021) Woo Dae Jang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 Dysregulation in COVID-19 Patients
- (2021) Francesco Sabbatino et al. Frontiers in Immunology
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- (2021) Eli S. Rosenberg et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis
- (2021) Valeria Conti et al. Journal of Personalized Medicine
- Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
- (2021) Mark W. Tenforde et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
- (2021) William A. Fischer et al. Science Translational Medicine
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
- (2021) George R Painter et al. Current Opinion in Virology
- The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
- (2021) Rana Abdelnabi et al. EBioMedicine
- Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
- (2021) Ching-Chi Lee et al. Antibiotics-Basel
- Molnupiravir: A new candidate for COVID‐19 treatment
- (2021) Fariba Pourkarim et al. Pharmacology Research & Perspectives
- Infections causing stroke or stroke-like syndromes
- (2020) Pasquale Pagliano et al. INFECTION
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Discovering small-molecule therapeutics against SARS-CoV-2
- (2020) Vaibhav Tiwari et al. DRUG DISCOVERY TODAY
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
- (2020) Ashleigh Shannon et al. Nature Communications
- Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
- (2020) Francesca Picarazzi et al. MOLECULES
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
- (2019) Ariane J. Brown et al. ANTIVIRAL RESEARCH
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
- (2019) Mart Toots et al. Translational Research
- β-D- N 4 -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
- (2017) Nadya Urakova et al. JOURNAL OF VIROLOGY
- Correction: Reynard, O.; et al. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. Viruses 2015, 7, 6233‒6240
- (2016) Viruses-Basel
- Base-Modified Nucleosides: Etheno Derivatives
- (2016) Zofia Jahnz-Wechmann et al. Frontiers in Chemistry
- The future of antivirals
- (2015) Yannick Debing et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Efficiency of Incorporation and Chain Termination Determines the Inhibition Potency of 2′-Modified Nucleotide Analogs against Hepatitis C Virus Polymerase
- (2014) Amy Fung et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
- (2014) Lisa Oestereich et al. ANTIVIRAL RESEARCH
- Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs
- (2014) Ugo Pradere et al. CHEMICAL REVIEWS
- Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
- (2013) Hidehiro Sangawa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
- (2013) B. J. Hart et al. JOURNAL OF GENERAL VIROLOGY
- Interspecies transmission and emergence of novel viruses: lessons from bats and birds
- (2013) Jasper Fuk-Woo Chan et al. TRENDS IN MICROBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search